Partners

Value Actualization

Our Contribution to Your Success

To be successful in Oncology, Rare Diseases and other scientifically complex indications, innovators know that they must adapt to an ever changing market. The historical "special status" in which products even with little demonstrated benefit were reimbursed, has been replaced by new evaluation criteria and increasing scrutiny. Nonetheless, it is still common for small and mid-sized companies with products in early development to postpone pricing and reimbursement considerations until preparing for commercialization or abdicating responsible to a commercialization partner not recognizing that strengthening their product VALUE PROPOSITION earlier in development and defining more clinically relevant and useful (real world) endpoints can increase bargaining power and associated royalty payments or an asset's selling price which translates directly into increased profitability.  It is no longer sufficient to develop an efficacious and safe product. Today's market is demanding products that demonstrate COMPARATIVE CLINICAL AND ECONOMIC EFFECTIVENESS or risk being non-reimbursable and therefore non-profitable.      

Value Genome LLC believes that innovative companies need to take a different approach by tailoring their clinical development program to reveal the CLINICAL and ECONOMIC VALUE of their assets as defined by relevant stakeholders including patients, professional and patient organizations, physicians and treatment centers, government and commercial payers and health technology assessment organizations. Innovators must establish and maintain interactions with stakeholders and elicit their preferences for how the clinical and economic value of their assets are quantified and communicated.    

Value Genome LLC can assist innovators optimize their clinical development programs. Value Genome LLC is a collaboration between former pharmaceutical and biotech executives who share a common passion for assisting technology innovators actualize the clinical and economic value of their assets. We combine our scientific, clinical, economic and commercialization expertise with our extensive PAYER RESEARCH and relations experience.  We enjoy partnering with technology innovators to ensure their many years of effort are translated into the highest possible financial return whether their goal is licensing, acquisition , or bringing a life changing product to market.

 

 

Value For Money

After years of industry experience working with our competitors we gained insights into the level of service that made us happy as clients and after conducting numerous clinical and cost comparative studies we appreciate the importance of having a superior product delivered at a competitive price. 

 

 
 

 Partners

 
 
VG bullett.png

 mANAGING Partner

Kevin Mayo, Ph.D., E.JD - Chief Market Access Officer

Dr. Kevin Walker Mayo is a founding partner for Value Genome LLC.  Prior to founding Value Genome LLC, Kevin was most recently Global Hemophilia Franchise Market Access and Patient Advocacy Head for Baxalta (now Shire). At Baxalta, Kevin lead a team of international market access and health economics experts responsible for negotiating with government and commercial payers to obtain pricing and formulary access for launching products. His responsibilities included conducting payer research and advisory boards to develop commercial strategies, developing and training his team upon value communication messages and negotiation tools and providing coordination for all health economics and outcomes research, pricing and reimbursement, tender management, advocacy and government affairs activities for a $6 billion portfolio.  Earlier in his career Kevin gained industry and consulting expertise in senior leadership roles with The Access Partnership, Endo Health Solutions, Bridgehead International, Daiichi Sankyo, Novartis Pharma AG and Pharmacia Corporation.

Kevin completed a Master’s degree in Neuropsychology from the University of Memphis and a Doctoral degree in Pharmaceutical Marketing and Administration from the University of Louisiana at Monroe.  More recently Kevin augmented his business education by completing an Executive Juris Doctorate in Health Law and Policy from Concord Law School.  He has served on the adjunct faculties for the Mayes College of Healthcare Business and Policy (University of the Sciences) and the College of Population Health (Thomas Jefferson University) and is a frequent presenter at international market access conferences.  Kevin received a Distinguished Service Award from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) for his contribution to the society.

 
 
 

 
 
 

Managing Partner

Edward Dow, M.D. - Chief Medical Officer 

Dr. Edward Dow is a founding partner and Value Genome LLC's Chief Medical Officer.  Prior to founding Value Genome LLC,  Ed worked for Baxalta (now Shire) as the Medical Director responsible for the Global Launch of Vonvendi, the first recombinant factor for von Willebrand disease. Ed's responsibilities included designing a post-launch registry, negotiating product labeling and training the global medical affairs team.  Earlier in his career Ed gained industry expertise with Foundation Medicine and Takeda Oncology.  Previously Ed spent 20 years working as a Medical Oncologist & Hematologist for the Lahey Clinic and New England Baptist Hospital. 

Ed completed a undergraduate degree in the History of Science at Harvard University and obtained his medical degree from Tufts University School of Medicine. 

 
 
 

 
 
 

Managing partner

Mark Rubino, R.PH, M.S. - Chief Pharmacy Officer 

Mark Rubino is founding partner and Chief Pharmacy Officer for Value Genome LLC. Prior to founding Value Genome LLC, Mark headed the Medical Science Liaison Team for Purdue Pharma and the Managed Markets Liaisons team for Endo Pharmaceuticals.  Mark's responsibilities included designing phase III clinical research trials, managing external research projects, leading internal data analytics research and disseminating comparative clinical and cost effectiveness evidence to Manged Care Organizations, government payers and Pharmacy Benefit Management firms.  Previous to joining industry, Mark served 14 years in senior leadership positions in Managed Markets Pharmacy as the Chief Pharmacy Officer for Aetna and the Vice President of Pharmacy for Medo. 

Mark completed a Pharmacy Degree at the University of Connecticut and a Masters degree in Healthcare Administration from Seton Hall University.